Mitigating the impact of fiber assignment on clustering measurements from deep galaxy redshift surveys

We examine the impact of fiber assignment on clustering measurements from fiber-fed spectroscopic galaxy surveys. We identify new effects which were absent in previous, relatively shallow galaxy surveys such as Baryon Oscillation Spectroscopic Survey . Specifically, we consider deep surveys covering a wide redshift range from z=0.6 to z=2.4, as in the Subaru Prime Focus Spectrograph survey. Such surveys will have more target galaxies than we can place fibers on. This leads to two effects. First, it eliminates fluctuations with wavelengths longer than the size of the field of view, as the number of observed galaxies per field is nearly fixed to the number of available fibers. We find that we can recover the long-wavelength fluctuation by weighting galaxies in each field by the number of target galaxies. Second, it makes the preferential selection of galaxies in under-dense regions. We mitigate this effect by weighting galaxies using the so-called individual inverse probability. Correcting these two effects, we recover the underlying correlation function at better than 1 percent accuracy on scales greater than 10 Mpc/h.Comment: 17 pages, 11 figure

Five-antituberculosis Drug-resistance Genes Detection Using Array System

Detection of resistance to drugs for Mycobacterium tuberculosis takes about two months from the sample collection using culture-based methods. To test a rapid method for detection of resistance for five antituberculosis drugs using DNA microarray and to examine its potential for clinical use, we employed a DNA microarray for detection of seven mutations genes related to resistance of five kinds of antituberculous drugs using Mycobacterium tuberculosis DNA isolated from sputum. The results of microarray analysis were compared with the results of a standard culture method of Lowenstein-jensen drug sensitivity testing system. DNA microarray analysis showed a high sensitivity (>90%) for all five drugs. Specificity of rifampicin and ethambutol were nearly 90%, however specificity of isoniazid (60%) and kanamycin (67%) were not enough. The amount of Mycobacterium tuberculosis DNA required for microarray analysis corresponded to at least 1–9 Acid-Fast Bacilli per 10 fields by carbolfuchsin staining. DNA microarray analysis appears to be useful for estimation of drug resistances, nevertheless its limitations. To minimize misunderstanding, it is necessary to confirm the number of bacilli in the sputum, and culture method is needed for comparison when use the PCR-based array system

Initial Results from the Nobeyama Molecular Gas Observations of Distant Bright Galaxies

We present initial results from the CO survey toward high redshift galaxies using the Nobeyama 45m telescope. Using the new wide bandwidth spectrometer equipped with a two-beam SIS receiver, we have robust new detections of three high redshift (z=1.6-3.4) submillimeter galaxies (SXDF 1100.001, SDP9, and SDP17), one tentative detection (SDSS J160705+533558), and one non-detection (COSMOS-AzTEC1). The galaxies observed during the commissioning phase are sources with known spectroscopic redshifts from previous optical or from wide-band submm spectroscopy. The derived molecular gas mass and line widths from Gaussian fits are ~10^11 Msun and 430-530 km/s, which are consistent with previous CO observations of distant submm galaxies and quasars. The spectrometer that allows a maximum of 32 GHz instantaneous bandwidth will provide new science capabilities at the Nobeyama 45m telescope, allowing us to determine redshifts of bright submm selected galaxies without any prior redshift information.Comment: 4 pages, 1 figure, PASJ Letter Accepte

Statistics of 207 Lya Emitters at a Redshift Near 7: Constraints on Reionization and Galaxy Formation Models

We present Lya luminosity function (LF), clustering measurements, and Lya line profiles based on the largest sample, to date, of 207 Lya emitters (LAEs) at z=6.6 on the 1-deg^2 sky of Subaru/XMM-Newton Deep Survey (SXDS) field. Our z=6.6 Lya LF including cosmic variance estimates yields the best-fit Schechter parameters of phi*=8.5 +3.0/-2.2 x10^(-4) Mpc^(-3) and L*(Lya)=4.4 +/-0.6 x10^42 erg s^(-1) with a fixed alpha=-1.5, and indicates a decrease from z=5.7 at the >~90% confidence level. However, this decrease is not large, only =~30% in Lya luminosity, which is too small to be identified in the previous studies. A clustering signal of z=6.6 LAEs is detected for the first time. We obtain the correlation length of r_0=2-5 h^(-1) Mpc and bias of b=3-6, and find no significant boost of clustering amplitude by reionization at z=6.6. The average hosting dark halo mass inferred from clustering is 10^10-10^11 Mo, and duty cycle of LAE population is roughly ~1% albeit with large uncertainties. The average of our high-quality Keck/DEIMOS spectra shows an FWHM velocity width of 251 +/-16 km s^(-1). We find no large evolution of Lya line profile from z=5.7 to 6.6, and no anti-correlation between Lya luminosity and line width at z=6.6. The combination of various reionization models and our observational results about the LF, clustering, and line profile indicates that there would exist a small decrease of IGM's Lya transmission owing to reionization, but that the hydrogen IGM is not highly neutral at z=6.6. Our neutral-hydrogen fraction constraint implies that the major reionization process took place at z>~7.Comment: 28 pages, 23 figures. Accepted for publication in Ap

Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model.

BACKGROUND: Graft-versus host disease (GVHD) is a complication of stem cell transplantation associated with significant morbidity and mortality. Non-specific immune-suppression, the mainstay of treatment, may result in immune-surveillance dysfunction and disease recurrence. METHODS: We created humanised mice model for chronic GVHD (cGVHD) by injecting cord blood (CB)-derived human CD34 FINDINGS: In cGVHD humanised mice, we found activation of T cells in the spleen, lung, liver, and skin, activation of macrophages in lung and liver, and loss of appendages in skin, obstruction of bronchioles in lung and portal fibrosis in liver recapitulating cGVHD. Acute GVHD humanised mice showed activation of T cells with skewed TCR repertoire without significant macrophage activation. INTERPRETATION: Using humanised mouse models, we demonstrated distinct immune mechanisms contributing acute and chronic GVHD. In cGVHD model, co-activation of human HSPC-derived macrophages and T cells educated in the recipient thymus contributed to delayed onset, multi-organ disease. In acute GVHD model, mature human T cells contained in the graft resulted in rapid disease progression. These humanised mouse models may facilitate future development of new molecular medicine targeting GVHD

Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus.

AIMS: Type 1 diabetes mellitus is associated with a high risk for bone fractures. Although bone mass is reduced, bone quality is also dramatically altered in this disorder. However, recent evidences suggest a beneficial effect of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) pathways on bone quality. The aims of the present study were to conduct a comprehensive investigation of bone strength at the organ and tissue level; and to ascertain whether enzyme resistant GIP or GLP-1 mimetic could be beneficial in preventing bone fragility in type 1 diabetes mellitus. MATERIALS AND METHODS: Streptozotocin-treated mice were used as a model of type 1 diabetes mellitus. Control and streptozotocin-diabetic animals were treated for 21 days with an enzymatic-resistant GIP peptide ([D-Ala2]GIP) or with liraglutide (each at 25 nmol/kg bw, ip). Bone quality was assessed at the organ and tissue level by microCT, qXRI, 3-point bending, qBEI, nanoindentation and Fourier-transform infrared microspectroscopy. RESULTS: [D-Ala2]GIP and liraglutide treatment did prevent loss of whole bone strength and cortical microstructure in the STZ-injected mice. However, tissue material properties were significantly improved in STZ-injected animals following treatment with [D-Ala(2) ]GIP or liraglutide. CONCLUSIONS: Treatment of STZ-diabetic mice with [D-Ala2]GIP or liraglutide was capable of significantly preventing deterioration of the quality of the bone matrix. Further studies are required to further elucidate the molecular mechanisms involved and to validate whether these findings can be translated to human patients. This article is protected by copyright. All rights reserved

Human AK2 links intracellular bioenergetic redistribution to the fate of hematopoietic progenitors

AK2 is an adenylate phosphotransferase that localizes at the intermembrane spaces of the mitochondria, and its mutations cause a severe combined immunodeficiency with neutrophil maturation arrest named reticular dysgenesis (RD). Although the dysfunction of hematopoietic stem cells (HSCs) has been implicated, earlier developmental events that affect the fate of HSCs and/or hematopoietic progenitors have not been reported. Here, we used RD-patient-derived induced pluripotent stem cells (iPSCs) as a model of AK2-deficient human cells. Hematopoietic differentiation from RD-iPSCs was profoundly impaired. RD-iPSC-derived hemoangiogenic progenitor cells (HAPCs) showed decreased ATP distribution in the nucleus and altered global transcriptional profiles. Thus, AK2 has a stage-specific role in maintaining the ATP supply to the nucleus during hematopoietic differentiation, which affects the transcriptional profiles necessary for controlling the fate of multipotential HAPCs. Our data suggest that maintaining the appropriate energy level of each organelle by the intracellular redistribution of ATP is important for controlling the fate of progenitor cells

Human NK cell development in hIL-7 and hIL-15 knockin NOD/SCID/IL2rgKO mice.

The immune system encompasses acquired and innate immunity that matures through interaction with microenvironmental components. Cytokines serve as environmental factors that foster functional maturation of immune cells. Although NOD/SCID/IL2rgKO (NSG) humanized mice support investigation of human immunity in vivo, a species barrier between human immune cells and the mouse microenvironment limits human acquired as well as innate immune function. To study the roles of human cytokines in human acquired and innate immune cell development, we created NSG mice expressing hIL-7 and hIL-15. Although hIL-7 alone was not sufficient for supporting human NK cell development in vivo, increased frequencies of human NK cells were confirmed in multiple organs of hIL-7 and hIL-15 double knockin (hIL-7xhIL-15 KI) NSG mice engrafted with human hematopoietic stem cells. hIL-7xhIL-15 KI NSG humanized mice provide a valuable in vivo model to investigate development and function of human NK cells

Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer

International audienceBACKGROUND: HuHMFG1 (AS1402) is a humanised monoclonal antibody that has undergone a phase I trial in metastatic breast cancer. The aim of this study was to characterise the pharmacokinetics (PKs) of HuHMFG1 using a population PK model. METHOD: Data were derived from a phase I study of 26 patients receiving HuHMFG1 at doses ranging from 1 to 16 mg kg(-1). Data were analysed using NONMEM software and covariates were included. A limited sampling strategy (LSS) was developed using training and a validation data set. RESULTS: A linear two-compartment model was shown to be adequate to describe data. Covariate analysis indicated that weight was not related to clearance. An LSS was successfully developed on the basis of the model, in which one sample is collected immediately before the start of an infusion and the second is taken at the end of infusion. CONCLUSION: A two-compartment population PK model successfully describes HuHMFG1 behaviour. The model suggests using a fixed dose of HuHMFG1, which would simplify dosing. The model could be used to optimise dose level and dosing schedule if more data on the correlation between exposure and efficacy become available from future studies. The derived LSS could optimise further PK assessment of this antibody

The Intracellular Transport and Secretion of Calumenin-1/2 in Living Cells

Calumenin isoforms 1 and 2 (calu-1/2), encoded by the CALU gene, belong to the CREC protein family. Calu-1/2 proteins are secreted into the extracellular space, but the secretory process and regulatory mechanism are largely unknown. Here, using a time-lapse imaging system, we visualized the intracellular transport and secretory process of calu-1/2-EGFP after their translocation into the ER lumen. Interestingly, we observed that an abundance of calu-1/2-EGFP accumulated in cellular processes before being released into the extracellular space, while only part of calu-1/2-EGFP proteins were secreted directly after attaching to the cell periphery. Moreover, we found the secretion of calu-1/2-EGFP required microtubule integrity, and that calu-1/2-EGFP-containing vesicles were transported by the motor proteins Kif5b and cytoplasmic dynein. Finally, we determined the export signal of calu-1/2-EGFP (amino acid positions 20–46) and provided evidence that the asparagine at site 131 was indispensable for calu-1/2-EGFP stabilization. Taken together, we provide a detailed picture of the intracellular transport of calu-1/2-EGFP, which facilitates our understanding of the secretory mechanism of calu-1/2